17.6 Transfusion‐transmitted parasitic and tick‐borne diseases
17.7 Other issues with transfusion‐transmitted infections
17.8 Other diseases of interest
17.9 Introduction of new test
References
23 18 The HLA System in Transfusion Medicine and Transplantation 18.1 The HLA system 18.2 Clinical HLA testing for transplantation 18.3 The human minor histocompatibility antigens 18.4 The HLA system and transplantation 18.5 The HLA system in transfusion therapy 18.6 Conclusion and summary References
24 19 Cellular Engineering 19.1 Hematopoietic progenitor and stem cells 19.2 General hematopoietic cellular engineering processes 19.3 Umbilical cord blood banking 19.4 Adoptive immunotherapy 19.5 Gene therapy for hereditary immune deficiencies and hemoglobin disorders 19.6 Immunotherapy for immune diseases 19.7 Mesenchymal stromal cells 19.8 Platelet‐rich plasma 19.9 Regulation of cellular engineering 19.10 Quality assurance and good manufacturing practices for cellular engineering References
25 20 Therapeutic Apheresis 20.1 Clinical uses of plasma exchange 20.2 Plasma exchange 20.3 Red cell exchange or erythrocytapheresis 20.4 Therapeutic cytapheresis 20.5 Photopheresis 20.6 Therapeutic apheresis using selective adsorption columns References
26 21 Quality Programs in Blood Banking and Transfusion Medicine 21.1 Quality improvement systems and high reliability 21.2 Quality assurance in the blood supply system 21.3 Errors in transfusion medicine 21.4 Quality assurance in transfusion therapy 21.5 Summary References
27 Index
List of Tables
1 Chapter 2Table 2.1 Key elements of a nationally coordinated blood transfusion service.Table 2.2 Activities related to blood availability and safety in different co...
2 Chapter 4Table 4.1 Strategies for collecting safe blood.Table 4.2 Complete list of medical history questions for blood donors.Table 4.3 General procedure: donor arm preparation for blood collection.Table 4.4 Adverse reactions to whole blood donation.Table 4.5 Potential complications and adverse reactions to cytapheresis donat...
3 Chapter 5Table 5.1 Some advantages and disadvantages of whole blood versus blood compo...Table 5.2 Components produced by blood banks and the medical use of these com...Table 5.3 Some of the products manufactured from whole blood subject to licen...Table 5.4 Content of anticoagulant–preservative solutions (mg in 63 mL).Table 5.5 Content of additive solutions.Table 5.6 Characteristics of red cells in AS‐1 (Adsol) for 42 days of storage...Table 5.7 Changes that occur during red cell storage: the storage lesion.Table 5.8 Established or potential adverse effects of leukocytes in blood com...Table 5.9 Platelet additive solution component concentration (mM).Table 5.10 Plasma‐derivative products.Table 5.11 Coagulation factor and inhibitor levels in 12 lots of Octaplas.
4 Chapter 6Table 6.1 Instruments available in the United States for collection of blood ...Table 6.2 Comparison of red cell units prepared from whole blood with red cel...Table 6.3 Effects of 10 μg/kg G‐CSF dose
